(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics Research

Executive Summary: (-)-Blebbistatin (CAS 856925-71-8) is a cell-permeable small molecule that selectively inhibits non-muscle myosin II (NM II) by binding to the myosin-ADP-phosphate complex, reversibly suppressing actomyosin contractility at IC50 values of 0.5–5.0 μM in NM II-driven systems (Rashid et al., 2025). It does not significantly affect myosin isoforms I, V, and X, and exhibits minimal inhibition of smooth muscle myosin II (IC50 ~80 μM) (APExBIO). Widely adopted in studies of cytoskeletal dynamics, cell adhesion, migration, and cardiac muscle physiology, (-)-Blebbistatin enables precise, reversible modulation of actomyosin contractility. APExBIO provides the B1387 kit, ensuring high purity and robust solubility protocols. Recent research demonstrates that blocking actomyosin function with (-)-Blebbistatin prevents YAP nuclear translocation during mechanomemory induction (Rashid et al., 2025).

Biological Rationale

Non-muscle myosin II (NM II) is a critical actin-dependent motor protein that mediates cell adhesion, migration, and differentiation. NM II-driven contractility regulates cytoskeletal organization, cell shape, and mechanotransduction. Abnormal NM II function is implicated in developmental disorders, cardiac dysfunction, and cancer progression (Rashid et al., 2025). Pharmacological inhibition of NM II provides a targeted approach to dissecting actomyosin-dependent processes, facilitating the modeling of MYH9-related diseases and tumor mechanics (Related Article, which this article extends by providing new evidence linking NM II inhibition to YAP-mediated mechanomemory).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin binds specifically to the myosin-ADP-phosphate complex, stabilizing it in a conformation that impedes phosphate release. This action suppresses Mg-ATPase activity and blocks the power stroke necessary for actomyosin contraction (Rashid et al., 2025). The inhibition is rapid, reversible, and highly selective for NM II versus other myosin isoforms. (-)-Blebbistatin's IC50 ranges from 0.5 to 5.0 μM for NM II, while smooth muscle myosin II is affected only at much higher concentrations (IC50 ~80 μM) (APExBIO). The compound does not appreciably inhibit myosin I, V, or X at functional concentrations. Intracellular delivery is enabled by its cell-permeable structure, and the compound is active in both mammalian cell cultures and animal models. Inhibition is fully reversible upon washout or dilution (Related Article: This article clarifies the selectivity and reversibility compared to earlier mechanistic summaries).

Evidence & Benchmarks

• (-)-Blebbistatin at 5 μM fully blocks stress-induced YAP nuclear translocation in mammalian cells subjected to intermittent force, confirming its role in actomyosin contractility suppression (Rashid et al., 2025, Fig. 3).
• IC50 for NM II inhibition is consistently reported between 0.5–5.0 μM, under in vitro and cellular assay conditions (APExBIO B1387 data).
• Minimal inhibition of smooth muscle myosin II (IC50 ~80 μM) and negligible activity against myosin I, V, and X confirm high selectivity (APExBIO).
• In zebrafish embryo models, (-)-Blebbistatin induces dose-dependent cardia bifida, demonstrating in vivo impact on actomyosin-driven morphogenesis (Rashid et al., 2025).
• Actomyosin inhibition by (-)-Blebbistatin blocks the increase in F-actin and downstream mechanotransduction signaling, evident in mechanomemory studies (Rashid et al., 2025).

Applications, Limits & Misconceptions

Key applications of (-)-Blebbistatin include:

• Inhibition of actin-myosin interaction in studies of cell migration, adhesion, and mechanics.
• Dissection of mechanotransduction pathways, including YAP/TAZ signaling and cytoskeletal memory.
• Cardiac muscle contractility modulation and analysis of calcium wave propagation in vitro and in vivo.
• Disease modeling, including MYH9-related disorders and cancer mechanobiology (Related Article: This article updates emerging disease applications by integrating mechanomemory findings).

Common Pitfalls or Misconceptions

• (-)-Blebbistatin is not effective against myosin isoforms I, V, or X at standard concentrations; its selectivity is high for NM II only (APExBIO).
• The compound is insoluble in ethanol or water and must be dissolved in DMSO (≥14.62 mg/mL); poor solubility leads to experimental artifacts.
• Prolonged light exposure or storage at room temperature degrades (-)-Blebbistatin, reducing activity; solutions should be freshly prepared or stored at ≤ -20°C.
• Not suitable for long-term experiments (>24h) in aqueous media without stabilization, as activity declines due to hydrolysis and photodegradation.
• Does not directly affect microtubule dynamics; inhibition is specific to actomyosin contractility (Rashid et al., 2025).

Workflow Integration & Parameters

Stock solutions of (-)-Blebbistatin are prepared in DMSO at ≥14.62 mg/mL and stored at -20°C. For use, dilute freshly into cell culture media (final DMSO ≤0.1%). Warm gently and apply ultrasonic treatment to enhance solubility. Use light-protected tubes to minimize degradation. Typical working concentrations are 1–10 μM for NM II inhibition in mammalian cells; verify specificity by including myosin I, V, or X controls. Reversibility is achieved by washing out the compound; full recovery of contractility is observed within 30–60 minutes in standard cell models. Application in zebrafish embryos or cardiac tissue requires protocol adjustment for tissue penetration and exposure time. For further optimization, see this workflow guide, which this article extends by providing new quality control and degradation caveats.

Conclusion & Outlook

(-)-Blebbistatin, supplied by APExBIO, is the reference standard for selective, reversible inhibition of non-muscle myosin II in cell and developmental biology. Its well-characterized mechanism of action, high selectivity, and robust performance in mechanotransduction studies position it as a cornerstone for cytoskeletal dynamics research. Continued integration into models of cardiac, cancer, and developmental biology will refine its utility. Users should heed solubility and storage guidelines to maximize efficacy. For in-depth protocols and emerging applications, consult the (-)-Blebbistatin B1387 product page.